Alumis, Inc. (ALMS)
6.18
-0.13
(-2.06%)
USD |
NASDAQ |
Oct 16, 11:26
Alumis SG&A Expense (TTM) : 77.08M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 77.08M |
| March 31, 2026 | 88.17M |
| December 31, 2025 | 91.86M |
| September 30, 2025 | 87.68M |
| June 30, 2025 | 78.74M |
| March 31, 2025 | 51.86M |
| December 31, 2024 | 35.20M |
| Date | Value |
|---|---|
| September 30, 2024 | 29.31M |
| June 30, 2024 | 24.70M |
| March 31, 2024 | 21.90M |
| December 31, 2023 | 20.50M |
| September 30, 2023 | 14.97M |
| June 30, 2023 | 9.00M |
| March 31, 2023 | 4.225M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Johnson & Johnson | 19.22B |
| Corcept Therapeutics, Inc. | 556.47M |
| Aclaris Therapeutics, Inc. | 23.24M |
| BioAge Labs, Inc. | 28.84M |
| ANI Pharmaceuticals, Inc. | 324.76M |